Name | Cvs Pharmacy #06184 |
---|---|
Organization Name | Ohio Cvs Stores Llc |
Location | 555 E State St, Athens, Ohio 45701 |
Type | Community/Retail Pharmacy |
Phone | (740) 593-8501 |
Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Ewing's Sarcoma is an aggressive pediatric cancer, most commonly caused by the improper fusion of the gene EWS with the gene FLI1. Though the cause has long been known, therapeutic targeting of this fusion has to date proven very difficult.
As the Senate Finance Committee finalizes its health reform proposal, medical-device makers are hoping to convince lawmakers to make one last change, The Wall Street Journal reports. "The Advanced Medical Technology Association, or AdvaMed, the trade group for the larger device manufacturers, wants [Committee Chair Max Baucus of Montana] to reduce $40 billion in fees over the next decade to $15 billion, according to people close to the negotiations. But industry was told that offer is too low.
Decompensated cirrhosis is a chronic disease linked to numerous complications in its final stage. Professor Jonel Trebicka from Goethe University was involved in carrying out a pilot study demonstrating that the long-term administration of albumin in high doses stabilizes the circulatory function of these patients and protects them from sepsis.
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a pivotal Phase 3 trial for the Company's sapacitabine oral capsules as a front-line treatment in elderly patients aged 70 years or older with newly diagnosed acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy.
In a guest post on the Global Health Technologies Coalition's "Breakthroughs" blog, Jamie Elizabeth Rosen, media and communications manager at Aeras, interviews Steven Reed, founder, president, and chief scientific officer of the Infectious Disease Research Institute (IDRI), "a 120-person non-profit biotech committed to applying innovative science to the research and development of products to prevent, detect, and treat infectious diseases of poverty."
› Verified 4 days ago
NPI Number | 1770259442 |
Type | Community/Retail Pharmacy |
Address | 555 E State St, Athens, OH 45701 |
Phone Number | 740-593-8501 |
News Archive
Ewing's Sarcoma is an aggressive pediatric cancer, most commonly caused by the improper fusion of the gene EWS with the gene FLI1. Though the cause has long been known, therapeutic targeting of this fusion has to date proven very difficult.
As the Senate Finance Committee finalizes its health reform proposal, medical-device makers are hoping to convince lawmakers to make one last change, The Wall Street Journal reports. "The Advanced Medical Technology Association, or AdvaMed, the trade group for the larger device manufacturers, wants [Committee Chair Max Baucus of Montana] to reduce $40 billion in fees over the next decade to $15 billion, according to people close to the negotiations. But industry was told that offer is too low.
Decompensated cirrhosis is a chronic disease linked to numerous complications in its final stage. Professor Jonel Trebicka from Goethe University was involved in carrying out a pilot study demonstrating that the long-term administration of albumin in high doses stabilizes the circulatory function of these patients and protects them from sepsis.
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a pivotal Phase 3 trial for the Company's sapacitabine oral capsules as a front-line treatment in elderly patients aged 70 years or older with newly diagnosed acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy.
In a guest post on the Global Health Technologies Coalition's "Breakthroughs" blog, Jamie Elizabeth Rosen, media and communications manager at Aeras, interviews Steven Reed, founder, president, and chief scientific officer of the Infectious Disease Research Institute (IDRI), "a 120-person non-profit biotech committed to applying innovative science to the research and development of products to prevent, detect, and treat infectious diseases of poverty."
› Verified 4 days ago
NPI Number | 1790888493 |
Organization Name | OHIO CVS STORES LLC |
Doing Business As | CVS PHARMACY #06184 |
Type | Durable Medical Equipment & Medical Supplies Supplier |
Address | 555 E State St, Athens, OH 45701 |
Phone Number | 740-593-8501 |
News Archive
Ewing's Sarcoma is an aggressive pediatric cancer, most commonly caused by the improper fusion of the gene EWS with the gene FLI1. Though the cause has long been known, therapeutic targeting of this fusion has to date proven very difficult.
As the Senate Finance Committee finalizes its health reform proposal, medical-device makers are hoping to convince lawmakers to make one last change, The Wall Street Journal reports. "The Advanced Medical Technology Association, or AdvaMed, the trade group for the larger device manufacturers, wants [Committee Chair Max Baucus of Montana] to reduce $40 billion in fees over the next decade to $15 billion, according to people close to the negotiations. But industry was told that offer is too low.
Decompensated cirrhosis is a chronic disease linked to numerous complications in its final stage. Professor Jonel Trebicka from Goethe University was involved in carrying out a pilot study demonstrating that the long-term administration of albumin in high doses stabilizes the circulatory function of these patients and protects them from sepsis.
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a pivotal Phase 3 trial for the Company's sapacitabine oral capsules as a front-line treatment in elderly patients aged 70 years or older with newly diagnosed acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy.
In a guest post on the Global Health Technologies Coalition's "Breakthroughs" blog, Jamie Elizabeth Rosen, media and communications manager at Aeras, interviews Steven Reed, founder, president, and chief scientific officer of the Infectious Disease Research Institute (IDRI), "a 120-person non-profit biotech committed to applying innovative science to the research and development of products to prevent, detect, and treat infectious diseases of poverty."
› Verified 4 days ago
News Archive
Ewing's Sarcoma is an aggressive pediatric cancer, most commonly caused by the improper fusion of the gene EWS with the gene FLI1. Though the cause has long been known, therapeutic targeting of this fusion has to date proven very difficult.
As the Senate Finance Committee finalizes its health reform proposal, medical-device makers are hoping to convince lawmakers to make one last change, The Wall Street Journal reports. "The Advanced Medical Technology Association, or AdvaMed, the trade group for the larger device manufacturers, wants [Committee Chair Max Baucus of Montana] to reduce $40 billion in fees over the next decade to $15 billion, according to people close to the negotiations. But industry was told that offer is too low.
Decompensated cirrhosis is a chronic disease linked to numerous complications in its final stage. Professor Jonel Trebicka from Goethe University was involved in carrying out a pilot study demonstrating that the long-term administration of albumin in high doses stabilizes the circulatory function of these patients and protects them from sepsis.
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a pivotal Phase 3 trial for the Company's sapacitabine oral capsules as a front-line treatment in elderly patients aged 70 years or older with newly diagnosed acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy.
In a guest post on the Global Health Technologies Coalition's "Breakthroughs" blog, Jamie Elizabeth Rosen, media and communications manager at Aeras, interviews Steven Reed, founder, president, and chief scientific officer of the Infectious Disease Research Institute (IDRI), "a 120-person non-profit biotech committed to applying innovative science to the research and development of products to prevent, detect, and treat infectious diseases of poverty."
› Verified 4 days ago
Cvs Pharmacy #06184 Type: Community/Retail Pharmacy Location: 555 E State St, Athens, Ohio 45701 Phone: (740) 593-8501 | |
Cvs Pharmacy #06193 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 32 S Court St, Athens, Ohio 45701 Phone: (740) 592-6024 | |
Kroger Pharmacy #901 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 919 E State St, Athens, Ohio 45701 Phone: (740) 566-4180 | |
Walmart Pharmacy 10-3486 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 929 E State St, Athens, Ohio 45701 Phone: (740) 594-3628 | |
Coler Drug Athens, Ltd Type: Pharmacy Location: 310 W Union St, Athens, Ohio 45701 Phone: (740) 447-9201 |